107 related articles for article (PubMed ID: 9774238)
1. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Bezard E; Stutzmann JM; Imbert C; Boraud T; Boireau A; Gross CE
Eur J Pharmacol; 1998 Sep; 356(2-3):101-4. PubMed ID: 9774238
[TBL] [Abstract][Full Text] [Related]
2. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Bezard E; Imbert C; Deloire X; Bioulac B; Gross CE
Brain Res; 1997 Aug; 766(1-2):107-12. PubMed ID: 9359593
[TBL] [Abstract][Full Text] [Related]
3. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study.
Benazzouz A; Boraud T; Dubédat P; Boireau A; Stutzmann JM; Gross C
Eur J Pharmacol; 1995 Sep; 284(3):299-307. PubMed ID: 8666012
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Boireau A; Dubedat P; Bordier F; Imperato A; Moussaoui S
Neuropharmacology; 2000 Apr; 39(6):1016-20. PubMed ID: 10727711
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Obinu MC; Reibaud M; Blanchard V; Moussaoui S; Imperato A
Mov Disord; 2002 Jan; 17(1):13-9. PubMed ID: 11835434
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of riluzole in MPTP-treated mice.
Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
[TBL] [Abstract][Full Text] [Related]
7. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
[TBL] [Abstract][Full Text] [Related]
8. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)].
Degryse AD; Colpaert FC
Brain Res Bull; 1986 May; 16(5):561-71. PubMed ID: 3488798
[TBL] [Abstract][Full Text] [Related]
9. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Boraud T; Bezard E; Stutzmann JM; Bioulac B; Gross CE
Neurosci Lett; 2000 Mar; 281(2-3):75-8. PubMed ID: 10704746
[TBL] [Abstract][Full Text] [Related]
10. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
[TBL] [Abstract][Full Text] [Related]
11. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
[TBL] [Abstract][Full Text] [Related]
13. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
14. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Schneider JS; Gonczi H; Decamp E
Brain Res; 2003 Nov; 990(1-2):38-44. PubMed ID: 14568327
[TBL] [Abstract][Full Text] [Related]
15. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Akai T; Yamaguchi M; Mizuta E; Kuno S
Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
[TBL] [Abstract][Full Text] [Related]
16. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
Irifune M; Nomoto M; Fukuda T
Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
[TBL] [Abstract][Full Text] [Related]
17. Behavioral evaluation of hemiparkinsonian MPTP monkeys following dopamine pharmacological manipulation and adrenal co-graft transplantation.
Howel LL; Byrd LD; McDonough AM; Iuvone PM; Bakay RA
Cell Transplant; 2000; 9(5):609-22. PubMed ID: 11144958
[TBL] [Abstract][Full Text] [Related]
18. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
19. Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia.
de Yébenes JG; Fahn S; Goodman R; Jamrosik Z; Pezzoli G; Popalski S
Adv Neurol; 1990; 53():231-8. PubMed ID: 1978516
[No Abstract] [Full Text] [Related]
20. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
